Drug Trial Radar · NCT01813435
GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation
Last checked: Nov 20, 2026Latest source record: Mar 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15,991
Actual
Start
Jul 1, 2013
Primary completion
Nov 9, 2015
Study completion Apr 26, 2018
Sponsor
- Lead sponsor
- ECRI bvIndustry
- Sponsor type
- Industry
- Collaborators
- Biosensors International; AstraZeneca; The Medicines Company
- First posted
- Mar 19, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
After a stent procedure, it is common practice to prescribe anti-platelet medication to prevent the blood from clotting. The main objective of this study is to determine if there is a better medication strategy to prevent blood from clotting and at the same time minimising the number of complications. There are two medication strategies: * Study group: Dual anti-platelet therapy (ticagrelor combined with aspirin) for 1 month, and then ticagrelor alone for another 23 months OR * Control group: Standard treatment, being dual anti-platelet therapy (ticagrelor or clopidogrel combined with aspirin) for 12 months, and then aspirin alone indefinitely
Conditions
- Coronary Artery Disease (CAD)
Interventions
TicagrelorDrug
Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy.
Acetylsalicylic AcidDrug
Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy
ClopidogrelDrug
Active Comparator: Reference treatment strategy Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy. Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With a Composite of All-cause Mortality or Non-fatal New Q-wave Myocardial Infarction (MI)Time frame: 2 year
Locations
130 sites in 18 countries. Site status is shown where the registry gives one.
Research centre Brisbane, 6101
Brisbane, Australia
Research centre Melbourne, 6104
Melbourne, Australia
Research centre Melbourne, 6105
Melbourne, Australia
Research centre Graz, 4305
Graz, Austria
Rsearch centre Innsbruck, 4303
Innsbruck, Austria
Research centre Linz, 4304
Linz, Austria
Research centre Vienna, 4301
Vienna, Austria
Research centre Vienna, 4302
Vienna, Austria
Research centre Aalst, 3201
Aalst, Belgium
Research centre Aalst, 3206
Aalst, Belgium
Research centre Bonheiden, 3204
Bonheiden, Belgium
Research centre Charleroi, 3202
Charleroi, Belgium
Research centre Genk, 3205
Genk, Belgium
Research centre Hasselt, 3203
Hasselt, Belgium
Research centre Rio de Janeiro, 5503
Rio de Janeiro, Brazil
Research centre Rio de Janeiro, 5504
Rio de Janeiro, Brazil
Research centre Sao Paulo, 5501
São Paulo, Brazil
Research centre Sao Paulo, 5502
São Paulo, Brazil
Research centre Uberlândia, 5505
Uberlândia, Brazil
Research centre Burgas, 9902
Burgas, Bulgaria
Research centre Plovdiv, 9905
Plovdiv, Bulgaria
Research centre Sofia, 9901
Sofia, Bulgaria
Research centre Sofia, 9903
Sofia, Bulgaria
Research centre Sofia, 9904
Sofia, Bulgaria
Research centre Sofia, 9907
Sofia, Bulgaria
Research centre Sofia, 9908
Sofia, Bulgaria
Research centre Varna, 9906
Varna, Bulgaria
Research centre Newmarket, 1003
Newmarket, Canada
Research centre Quebec, 1001
Québec, Canada
Research centre Copenhagen, 4501
Copenhagen, Denmark
Research centre Roskilde, 4503
Roskilde, Denmark
Research centre Aix en Provence, 3311
Aix-en-Provence, France
Research centre Caen, 3308
Caen, France
Research centre Caen, 3309
Caen, France
Research centre Clermont-Ferrand, 3303
Clermont-Ferrand, France
Research centre Dijon, 3313
Dijon, France
Research centre Grenoble, 3312
Grenoble, France
Research centre Lyon, 3316
Lyon, France
Research centre Nancy, 3314
Nancy, France
Research centre Paris, 3301
Paris, France
Showing 40 of 130 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.